Pushing the boundaries of innovation: the potential of ex vivo organ perfusion from an interdisciplinary point of view
J Iske, A Schroeter, S Knoedler… - Frontiers in …, 2023 - frontiersin.org
Ex vivo machine perfusion (EVMP) is an emerging technique for preserving explanted solid
organs with primary application in allogeneic organ transplantation. EVMP has been …
organs with primary application in allogeneic organ transplantation. EVMP has been …
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
G Goeckenjan, H Sitter, M Thomas, D Branscheid… - …, 2010 - thieme-connect.com
Qualitätsindikatoren wurden durch Sens et al. wie folgt definiert:„Ein Indikator ist ein
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
W Schütte, S Gütz, W Nehls, TG Blum, W Brückl… - …, 2023 - thieme-connect.com
Die aktuelle Fassung der Leitlinie Lungenkarzinom trägt der Dynamik der Informationen in
diesem Fachbereich Rechnung. Insbesondere gelten folgenden Empfehlungen: Die …
diesem Fachbereich Rechnung. Insbesondere gelten folgenden Empfehlungen: Die …
Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer
SA Laurie, D Logan, BR Markman, JA Mackay… - Lung cancer, 2004 - Elsevier
An evidence-based practice guideline was developed to identify the optimal combination
chemotherapy regimen, schedule of administration, and duration of therapy for the first-line …
chemotherapy regimen, schedule of administration, and duration of therapy for the first-line …
First-line chemotherapy in metastatic small-cell lung cancer (SCLC)
M Wolf, S Tebbe, T Fink - Lung Cancer, 2004 - Elsevier
The overall treatment results in metastatic small-cell lung cancer have not been changed in
the last decades. The prognosis of the disease is still poor with median survival times of less …
the last decades. The prognosis of the disease is still poor with median survival times of less …
[HTML][HTML] A Phase II randomised trial comparing the cisplatin–etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell …
JP Sculier, JJ Lafitte, J Lecomte, T Berghmans… - Annals of oncology, 2002 - Elsevier
Background A phase II randomised trial was performed with patients with SCLC to
determine if the addition of carboplatin to cisplatin–etoposide might improve the response …
determine if the addition of carboplatin to cisplatin–etoposide might improve the response …
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—a phase II study
M Reck, U Jagos, F Grunwald, E Kaukel, G Koschel… - Lung Cancer, 2003 - Elsevier
Purpose: We evaluated the toxicity and feasibility of adding paclitaxel to a standard
platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer …
platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer …
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer
JM Vieitez, M Valladares, M Gracia, M Gonzalez-Baron… - Lung cancer, 2003 - Elsevier
Purpose: To evaluate the efficacy and tolerability of paclitaxel, carboplatin and etoposide
when administered in combination to previously-untreated small-cell lung cancer (SCLC) …
when administered in combination to previously-untreated small-cell lung cancer (SCLC) …